Protocol Ledger

NCT07015190 · Phase III · RECRUITING

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Interventional Phase III clinical trial protocol NCT07015190 sponsored by IDEAYA Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-25 Enrollment: 520 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07015190
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)520 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07015190
Protocol FieldVerified Registry Value
NCT IdentifierNCT07015190
Consolidated Lead SponsorIDEAYA Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment520 participants (ESTIMATED)
Registered Start Date2026-01-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI